EP1148837B1 - System for controlling thermal therapy - Google Patents
System for controlling thermal therapy Download PDFInfo
- Publication number
- EP1148837B1 EP1148837B1 EP99965224A EP99965224A EP1148837B1 EP 1148837 B1 EP1148837 B1 EP 1148837B1 EP 99965224 A EP99965224 A EP 99965224A EP 99965224 A EP99965224 A EP 99965224A EP 1148837 B1 EP1148837 B1 EP 1148837B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- temperature
- tissue
- coolant
- catheter
- coolant temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00084—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00023—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids closed, i.e. without wound contact by the fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00547—Prostate
Definitions
- the present invention relates to a thermal therapy system for treating tissue such as the prostate with enhanced treatment effectiveness and minimal treatment time.
- the prostate gland is a complex, chestnut-shaped organ which encircles the urethra immediately below the bladder. Nearly one third of the prostate tissue anterior to the urethra consists of fibromuscular tissue that is anatomically and functionally related to the urethra and the bladder. The remaining two thirds of the prostate is generally posterior to the urethra and is comprised of glandular tissue.
- the portion of the urethra extending through the prostate i.e., the prostatic urethra
- BPH benign prostatic hyperplasia
- cancer benign prostatic hyperplasia
- BPH is a nonmalignant, bilateral expansion of prostate tissue occurring mainly in the transition zone of the prostate adjacent to the proximal segment of the prostatic urethra. As this tissue grows in volume, it encroaches on the urethra extending into the region of the bladder neck at the base of the bladder. Left untreated, BPH causes obstruction of the urethra which usually results in increased urinary frequency, urgency; incontinence, nocturia and slow or interrupted urinary stream. BPH may also result in more severe complications, such as urinary tract infection, acute urinary retention, hydronephrosis and uraemia.
- Benign prostatic hyperplasia may be treated using transurethral thermal therapy as described in further detail in U.S. Patent 5,620,480 entitled METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA WITH THERMAL THERAPY and in U.S. Patent 5,575,811 entitled BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING,
- Transurethral thermal therapy is administered by use of a microwave antenna-containing catheter which includes a multi-lumen shaft.
- the catheter is positioned in the urethra with the microwave antenna located adjacent to the hyperplastic prostatic tissue. Energization of the microwave antenna causes the antenna to emit electromagnetic energy which heats tissue within the prostate. A cooling fluid is circulated through the catheter to preserve tissue such as the urethral wall between the microwave antenna and the target tissue of the prostate.
- US 5 755 754 discloses the system of the preamble of appended claim 1.
- transurethral thermal therapy The primary goal of transurethral thermal therapy is to necrose prostate tissue while preserving adjacent healthy tissue. It is also preferable to achieve this goal in as short of a time as is possible, consistent with the patient's level of tolerance and comfort. In addition, it is important that the rectum be preserved from unduly high temperatures, since it is susceptible to thermal damage. There is an ongoing need in the art for a method of controlling thermal therapy that reduces treatment time and enhances effectiveness consistent with all of these parameters.
- the present invention is a thermal therapy system for treating tissue with heat from an adjacent body cavity, such as treating a prostate with heat delivered from a urethra as defined in appended claim 1.
- An applicator is insertable into the body cavity, and includes a microwave antenna and at least one cooling fluid chamber for circulating a coolant between the microwave antenna and a wall of a body cavity in which the applicator is capable of insertion.
- a microwave generator is operable to energize the microwave antenna in the applicator, and a coolant temperature controller is operable to control a temperature of the coolant circulating between the microwave antenna and the wall of the body cavity.
- a control system selectively operates the microwave generator and the coolant temperature controller to adjust the temperature of the coolant according to a predetermined coolant temperature profile, continually adjust coolant temperature based on therapy parameters, and maintain the applicator at a temperature corresponding to a predetermined applicator temperature profile by controlling the temperature of the coolant in coordination with a power level provided to the microwave antenna.
- the targeted tissue region is the prostate adjacent the urethra
- rectal temperature is monitored and, upon sensing a predetermined rectal temperature profile, coolant temperature is adjusted. Coolant temperature may also be adjusted based on patient comfort indicators.
- the applicator is maintained at a temperature corresponding to a predetermined applicator temperature profile by adjusting a power level provided to the microwave antenna.
- FIG. 1 is a vertical sectional view of a male pelvic region showing the effect benign prostatic hyperplasia (BPH) has on the urinary organs.
- Urethra 10 is a duct leading from bladder 12, through prostate 14 and out orifice 16 of penis end 18. Benign tumorous tissue growth within prostate 14 around urethra 10 causes constriction 20 of urethra 10, which interrupts the flow of urine from neck 22 of bladder 12 to orifice 16.
- the tumorous tissue of prostate 14 which encroaches urethra 10 and causes constriction 20 can be effectively removed by heating and necrosing the encroaching tumorous tissue.
- periurethral tumorous tissue of prostate 14 anterior and lateral to urethra 10 is heated and necrosed to avoid unnecessary and undesirous damage to urethra 10 and to adjacent healthy tissues, such as ejaculatory duct 24 and rectum 26.
- a selective heating of benign tumorous tissue of prostate 14 may be achieved by utilizing a microwave antenna-containing catheter such as is shown in U.S. Patent 5,620,480 or U.S. Patent 5,575,811 .
- FIG. 2 shows an enlarged view of the male pelvic region of FIG. 1 with a catheter 27 simplistically shown properly positioned within urethra 10. While the particular structure of catheter 27 may vary and a number of lumens may be provided therein, catheter 27 typically includes transmission line 28 connected to microwave antenna 30 for emitting microwave energy to prostate 14. Cooling fluid is circulated along paths 32 between microwave antenna 30 and the walls 36 of urethra 10, so as to conductively cool the tissue of urethra 10 when microwave antenna 30 is energized to radiate microwave energy to prostate 14.
- Catheter 27 may be secured within urethra 10 by retention balloon 34 located in bladder 12, for example. The temperature of the urethra may be detected by providing a temperature sensor on catheter 27 contacting urethral walls 36.
- the temperature of rectum 26 may be detected by inflating a balloon or providing another type of device in rectum 26 that includes a temperature sensor in contact with the rectal wall, such as is disclosed in U.S. Patent 5,792,070 entitled RECTAL THERMOSENSING UNIT, (particular reference being made to FIG. 1 , which illustrates an inflated rectal thermosensing unit carrying a temperature sensor, and the accompanying description at column 3, line 24 - column 5, line 42).
- FIG. 3 is a cross-sectional view of a first exemplary urethral catheter 27a.
- urethral catheter 27a includes ridges 38, sleeve 40, outer thermal sensing lumen 41, apertures 42A and 42B, chamber 43, microwave antenna lumen 44, urine drainage lumen 46, coolant fluid return lumen 48, inflation lumen 52, inner thermal sensing lumen 54, fluid channels 58 and 60, antenna jacket 61, and coolant fluid supply shaft 63.
- Outer thermal sensing lumen 41 and inner thermal sensing lumen 54 contain a thermal sensor which monitors the temperature of urethra 10 during therapy.
- Antenna jacket 61 securely contains a microwave antenna (not shown in FIG. 3 ) during therapy.
- Fluid channel 60 provides a supply path for the cooling fluid between coolant fluid supply shaft 63 and chamber 43 while fluid channel 58 provides a return path for the cooling fluid between chamber 43 and lumen 48.
- the cooling fluid is circulated from coolant fluid supply shaft 63 into chamber 43 via aperture 42B and fluid channel 60.
- the cooling fluid fills chamber 43 defined by catheter shaft 33 and PET sleeve 40.
- the cooling fluid returns to catheter shaft 33 through coolant fluid return lumen 48 via aperture 42A and fluid channel 58.
- FIG. 4 is a cross-sectional view of a second exemplary urethral catheter 27b.
- Cooling fluid intake lumens 74A, 74B are positioned circumjacent first side 78 of shaft 31 and antenna lumen 68. Cooling fluid intake lumens 74A and 74B extend from the distal shaft end to the proximal shaft end. Intake lumens 74A and 74B are relatively narrow in cross-section and have a relatively small cross-sectional surface area. Water contained within intake lumens 74A and 74B performs two essential functions. First, water contained within lumens 74A and 74B absorbs some of the microwave energy emitted by an antenna contained in antenna lumen 68.
- water within lumens 74A and 74B absorbs heat energy generated by the microwave energy from adjacent tissues (i.e., urethra 10) via thermal conduction. This prevents urethra 10 adjacent first side 78 from being overheated and damaged when the antenna is energized.
- Cooling fluid exhaust lumens 76A and 76B are circumjacent second side 82 and antenna lumen 68. Like intake lumens 74A and 74B, exhaust lumens 76A and 76B extend from the shaft distal end to the shaft proximal end. Exhaust lumens 76A and 76B are wider in cross-section than intake lumens 74A and 74B, and have a cross-sectional area greater than the cross-sectional area of intake lumens 74A and 74B. Water within exhaust lumens 76A, 76B is therefore capable of absorbing a greater amount of microwave energy when the antenna is energized.
- the temperature of tissue adjacent second side 82 will remain below about 45° C.
- Water within exhaust lumens 76A, 76B also absorbs heat energy from adjacent tissue (i.e., urethra 10) when the antenna is energized, which prevents urethra 10 adjacent second side 82 from being overheated and damaged when the antenna is energized.
- FIG. 5 is a block diagram of an exemplary transurethral microwave thermal therapy system 92, with which urethral catheter 27 is used.
- System 92 includes cooling system 86, microwave generating source 84, user interface 94, real time controller (RTC) 96, directional coupler 100, thermometry sensors 102 and 104, coolant pressure sensor 114, balloon inflation device 110, and urine collection container 112.
- RTC real time controller
- control of microwave generating source 84 and cooling system 86 is effected by RTC 96, which is in turn controlled by user interface 94.
- user interface 94 is an IBM compatible machine containing two hard drives for data storage: one for backup, and one for normal operation of system 92.
- User interface 94 communicates with RTC 96, which is responsible for closed-loop feedback to run system 92.
- RTC 96 has direct closed-loop control of microwave power from microwave generating source 84, and coolant flow and coolant temperature of cooling system 86. The closed-loop feedback of RTC 96 tracks out variations in gain, drift and cable losses inherent in microwave generating source 84.
- RTC 96 also tracks the variability in pump output and refrigeration system efficiency of cooling system 86. In addition to monitoring microwave generation source 84 and cooling system 86, RTC 96 also monitors and controls several channels of thermometry via inputs from thermometry unit 98.
- Cooling system thermometry 98A measures the coolant and chiller temperatures based upon signals from cooling temperature sensor 102 and 104 and a chiller temperature sensor (not shown) of cooling system 86.
- Urethral thermometry 98B measures urethral temperature based upon signals from a temperature sensor within catheter 27.
- Rectal thermometry 98C measures rectal temperature based upon signals received from a sensor (not shown) within rectal probe 108.
- RTC 96 transmits closed-loop feedback to user interface 94, which processes the input and transmits corrections and instructions back to RTC 96.
- RTC 96 interprets the instructions given to it by process control language received from user interface 94 and executes the instructions in real time. Corrections from user interface 94 are made to maintain a desired thermal profile throughout the transurethral thermal therapy.
- system 92 includes a hardware fail-safe circuit which shuts down system 92 should any parameter fall outside a given range of values.
- FIGS. 6A and 6B are graphs illustrating basic tissue temperature/depth curves at different power levels and coolant temperatures during thermal therapy, and demonstrating the basic principles of the present invention.
- FIG. 6A illustrates tissue temperature/depth curves for a treatment session where catheter temperature is held at a predetermined value (such as 40°C)
- FIG. 6B illustrates tissue temperature/depth curves for a treatment session where a certain depth of tissue around the catheter is held at a predetermined value (such as 40°C).
- the vertical axes of FIGS. 6A and 6B represent the temperature of tissue
- the horizontal axes represent the depth from the catheter/urethra of that tissue. Therefore, a depth of zero represents the urethral wall.
- Curve 120 represents a situation where microwave power is zero and coolant temperature is equal to the steady-state catheter temperature (e.g., 40°C)
- curve 122 represents a situation where the microwave power is high and coolant temperature is at a minimum (such as 8°C, for illustrative purposes) and the curves between curve 120 and curve 122 represent situations where the microwave power is between zero and the high value
- the coolant temperature is between the steady-state catheter temperature (e.g., 40°C) and (the minimum coolant temperature (e.g., 8°C).
- each curve is labeled according to the relative coolant temperature (t c ) and power level (p), so that curve 120 represents the highest coolant temperature (t c1 ) and the lowest power (p 7 ) and curve 122 represents the lowest coolant temperature (t c7 ) and the highest power level (p 1 ), wherein each curve is predicated on the condition that catheter temperature is maintained at a steady-state temperature such as 40°C.
- the particular values of the minimum coolant temperature and corresponding power level depend on -the structure and characteristics of the treatment catheter employed, and it should be understood that the exemplary values provided herein refer only to one particular catheter structure; othervalues are appropriate for different catheter structures, while still practicing the present invention. As can be seen from the curves shown in FIG.
- Each of the curves shown in FIG. 6B also represent a different coolant temperature and microwave power condition, with the constant criteria for each curve being that the temperature of tissue at a depth of interest, defining a zone of protection from the outer surface of the catheter to that tissue depth (such as 1 millimeter, for example), is maintained at a steady-state temperature such as 40°C.
- Curve 124 represents a situation where microwave power is slightly greater than zero and coolant temperature is equal to a temperature slightly greater than the steady-state tissue temperature (e.g., 40°C), which is slightly different from the power and coolant temperature shown in curve 120 ( FIG. 6A ) where the catheter rather than a depth of tissue was maintained at a steady-state temperature such as 40°C.
- Curve 126 represents a situation where the microwave power is high and coolant temperature is at a minimum (such as 8°C, for illustrative purposes) and the curves between curve 124 and curve 126 represent situations where the microwave power is between zero, and the high value, and the coolant temperature is between the steady-state tissue temperature (e.g., 40°C) and the minimum coolant temperature (e.g., 8°C).
- each curve is labeled according to the relative coolant temperature (t c ) and power level (p), so that curve 124 represents the highest coolant temperature (t c1 ) and the lowest power (p 7 ) and curve 126 represents the lowest coolant temperature (t c7 ) and the highest power level (p 1 ), wherein each curve is predicated on the condition that tissue temperature is maintained at a steady-state temperature such as 40°C.
- the particular values of the minimum coolant temperature and corresponding power level depend on the structure and characteristics of the treatment catheter employed, and it should be understood that the exemplary values provided herein refer only to one particular catheter structure; other values are appropriate for different catheter structures, while still practicing the present invention. As can be seen from the curves shown in FIG.
- temperatures at the depth of the rectum may become unacceptably high. In other words, high temperatures are achieved at too great of a depth from the catheter/urethra. Therefore, in a preferred method of controlling thermal therapy, rectal temperature is utilized as a parameter for controlling the coolant temperature (and the catheter/tissue temperature set point, temporarily) to enable optimal therapy without thermally damaging the tissue of the rectum.
- FIG. 7A is a block diagram illustrating a complete thermal therapy control method according to a first embodiment of the present invention, utilizing the principles and parameters discussed above with respect to FIG. 6A .
- a physician enters inputs related to catheter temperature at block 130a and inputs related to coolant temperature at block 132. Specifically, a physician enters an initial ramp rate of catheter temperature (that is, how quickly and in what manner the catheter temperature is to increase from its initial temperature of approximately body temperature (37°C) to its final, steady-state temperature) and a steady-state catheter temperature.
- the physician enters a coolant temperature ramp rate (that is, how quickly and in what manner the coolant temperature is to decrease from its initial temperature to a targeted final temperature), an initial coolant temperature and a steady-state coolant temperature.
- the catheter temperature ramp rate and the coolant temperature ramp rate may comprise a ramping function, such that cathetertemperature and/or coolant temperature increases or decreases exponentially, linearly, or according to some other function that enhances the effectiveness of the therapy consistent with patient comfort concerns.
- the exact value and degree of physician contribution of these inputs will depend on experimental results of therapy in particular patients, and are set consistent with a desired patient comfort level.
- physician input may also be simplified by an appropriate software program or other means, so that the physician enters only minimal data and the program calculates the therapy inputs from the data entered by the physician.
- the physician inputs are further explained graphically below with respect to FIGS. 8A and 8B .
- a catheter temperature profile is established at block 138.
- the catheter temperature profile represents a desired characteristic of catheter temperature at a particular time in the thermal therapy session, which may of course be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below.
- a coolant temperature profile is established at block 134.
- the coolant temperature profile also represents a desired characteristic of coolant temperature at a particular time in the thermal therapy session, which again may be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below.
- the catheter temperature profile signal is passed on to adder/subtractor 136, which passes a modified cathetertemperature set point signal on to Microwave Power Control block 140, which in one preferred embodiment is implemented as a proportional/integrat/differential (PID) control loop.
- PID control loops are algorithms known in the art for controlling a process to achieve a desired output level.
- the power delivered to the microwave antenna 30 ( FIG. 2 ) energizes the antenna to radiate electromagnetic energy, resulting in elevation of prostate tissue temperature as represented by block 142. Power delivered to the microwave antenna is continually adjusted to ensure that the catheter remains at the modified catheter temperature set point; therefore, Microwave Power Control block 140 is responsive to the measured catheter temperature at block 148 to adjust microwave power accordingly.
- Elevation of prostate tissue temperature at block 142 causes a biological response in the tissue, which is represented by block 144.
- One response is increased blood perfusion in the tissue, which tends to conduct heat away from a particular portion of tissue and reduce the heating effect on the tissue.
- the temperature of the rectum may also be increased. Rectal temperatures are therefore monitored during thermal therapy to ensure that the rectum is not thermally damaged by excessively high temperatures; the measured rectal temperature is represented by block 146. If rectal temperature reaches a predetermined threshold, steps must be taken to reduce the temperature of the rectum so that it may be preserved.
- the catheter temperature is initially reduced in response to high rectal temperatures by a catheter temperature modifier represented at block 150.
- the catheter temperature modifier is subtracted by adder/subtractor 136 from the desired catheter temperature provided by the catheter temperature profile to yield a modified catheter temperature set point, which is input to Microwave Power Control block 140.
- a Coolant Temperature Control block 152 implements a PID control loop, for example, to determine an increased temperature of the coolant.
- Comparator block 154 outputs the higher of the coolant temperature provided by the coolant temperature profile at block 134 and the coolant temperature provided by Coolant Temperature Control block 152.
- the desired coolant temperature is determined by the coolant temperature profile at block 134 unless an excessively high rectal temperature causes a higher coolant temperature to be determined by Coolant Temperature Control block 152.
- the desired coolant temperature is input to Cooler/Heater Control block 156 along with the measured coolant temperature at block 160, and Cooler/Heater Control block 156 implements a PID control loop, for example, to adjust coolant temperature and stabilize the coolant at the appropriate temperature.
- the actual coolant temperature affects the temperature of the catheter and temperature to which prostate tissue and the rectum are elevated, which is represented by the line from Cooler/Heater Control block 156 to the tissue temperature elevation shown at block 142.
- the catheter temperature modifier is reduced to zero, and the catheter temperature returns to the value provided by the catheter temperature profile at block 138, with the system stabilizing at the higher coolant temperature.
- rectal temperatures and prostate tissue temperatures
- catheter temperatu re set point at the maximum desired value consistent with patient comfort.
- coolant temperature should be increased in response to excessively high temperatures in the rectum, but it is nonetheless true where the catheter temperature is constrained to a predetermined steady-state value, since an increase in coolant temperature effectively forces a reduction in power provided to the microwave antenna to maintain the catheter at the steady-state value.
- the method of the present invention therefore enhances the effectiveness and reduces the necessary treatment time of the therapy.
- the thermal therapy controlled by the method of the present invention must take into account the comfort level of the patient at various phases of the therapy.
- the catheter temperature ramp rate or ramping function or the steady-state catheter temperature may potentially drive changes in power that may result in discomfort for the patient.
- the coolant temperature ramp rate or ramping function or other parameters may also result in power level changes that could potentially cause some patient discomfort.
- a physician may adjust the therapy at any time in response to an indication of patient discomfort, represented by block 158. Patient discomfort may potentially occur as a result of high absolute temperatures, or also as a result of high rates of change of temperatures, and therapy therefore is adjustable to change parameters related to both of these factors.
- the therapy parameter changes implemented by the physician are integrated into the therapy control method of the present invention to reduce or eliminate the discomfort of the patient.
- FIG. 7B is a block diagram illustrating a complete thermal therapy control method according to a second embodiment of the present invention, utilizing the principles and parameters discussed above with respect to FIG. 6B .
- the majority of the method shown in FIG. 7B is identical to that shown in FIG. 7A , with one principal modification.
- the modified method shown in FIG. 7B is concerned with a tissue temperature set point (that is, the temperature in tissue at some depth of interest from the catheter/urethra, defining a tissue protection zone).
- a physician enters an initial tissue temperature ramp rate/ramping function and a steady-state tissue temperature at block 130b, in a manner substantially similar to that described with respect to block 130a of FIG. 7A .
- a tissue temperature profile is established at block 138b, which represents a desired characteristic of tissue temperature at a particular time in the thermal therapy session, which may of course be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below.
- the tissue temperature profile signal is passed on to adder/subtractor 136, which passes a modified tissue temperature set point signal on to Microwave Power Control block 140, which is implemented as described above with respect to FIG. 7A .
- the power delivered to microwave antenna 30 ( FIG. 2 ) energizes the antenna to radiate electromagnetic energy, resulting in elevation of prostate tissue as represented by block 142. Power delivered to the microwave antenna is continually adjusted to ensure that tissue at the depth of interest remains at the modified tissue temperature set point. In order to do so, Microwave Power Control block 140 must be responsive to tissue temperature. However, tissue temperature at a depth from the catheter/urethra typically cannot be measured directly without penetrating the urethra.
- catheter temperature is measured at block 148, and tissue temperature is calculated at block 149 based on the measured catheter temperature (block 148), the microwave power level (block 140) and the measured coolant temperature (block 160).
- Microwave Power Control block 140 is therefore responsive to the calculated tissue temperature at block 149 to adjust microwave power accordingly.
- a temperature sensor may be positioned in the tissue by penetrating the urethra, or some other temperature sensing system for directly measuring tissue temperature may be implemented, in which case the measured tissue temperature would replace measured catheter temperature at block 148 of FIG. 7A , and there would be no need to calculate tissue temperature.
- Rectal temperatures are also monitored during thermal therapy to ensure that the rectum is not thermally damaged by excessively high temperatures; the measured rectal temperature is represented by block 146. If rectal temperature reaches a predetermined threshold, steps must be taken to reduce the temperature of the rectum so that it may be preserved. As described above with respect to FIG. 7A , since coolant temperature may not be able to be instantaneously increased, the temperature set point is initially decreased to force microwave power to be immediately reduced. This tissue temperature set point is reduced by the tissue temperature modifier represented at block 150b, which is subtracted by adder/subtractor 136 from the desired tissue temperature to yield a modified tissue temperature set point input to Microwave Power Control block 140. As also described above with respect to FIG.
- the tissue temperature modifier is reduced to zero, and the tissue temperature returns to the value provided by the tissue temperature profile at block 138b, with the system stabilizing at the higher coolant temperature.
- FIG. 8A is a graph illustrating measured temperatures achieved during an actual thermal therapy treatment session in a clinical trial according to one variation of the control method of the present invention.
- anesthesia was used to ensure that the patients remained comfortable, so the patient comfort adaptability of the present invention was not utilized in the trial.
- Curve 180 represents the temperature of the catheter inserted into the urethra of the patient.
- Curve 182 represents the temperature of the coolant circulated between the antenna in the catheter and the urethral wall; the small oscillations in curve 182 are due to the heating/cooling system utilized in the trial.
- Curve 184 represents the microwave power level delivered to the antenna.
- Curve 188 represents the temperature of tissue at a depth of approximately 0.5 cm in the prostate surrounding the urethra.
- the step-wise decrease in coolant temperature was set by the physician as the coolanttemperature ramp rate (block 132, FIG. 7A ); again, the ramp rate and ramping function can vary as described above.
- the temperature of prostate tissue curve 188) increased in a corresponding step-wise manner to the coolant temperature decrease.
- Coolant temperature finally reached a steady-state temperature, which again had been set by the physician at block 132, FIG. 7A .
- rectal temperature was monitored to ensure that temperatures do not exceed a predetermined threshold, to prevent thermal damage to the rectum; no excessively high rectal temperatures were detected.
- the catheter temperature set point (curve 180) was increased from 40°C to 42°C for experimental purposes.
- the increase in steady-state catheter temperature resulted in a corresponding increase in power (curve 184) and tissue temperature (curve 188), while the coolant temperature (curve 182) was kept constant.
- Microwave power curve 184, catheter temperature curve 180 and tissue temperature curve 188 experience some oscillation at a treatment time between 40 and 50 minutes. These oscillations were due to a bladder spasm experienced by the patient at this time, which may occur from time to time during a thermal therapy treatment session. During the bladder spasm, although catheter temperature oscillated briefly, the control method of the present invention caused it to remain at a level approximately equal to or below the catheter temperature set point, and catheter temperature returned to the steady-state temperature automatically and stabilized with no outside intervention when the bladder spasm ceased.
- FIG. 8B is a graph illustrating measured temperatures achieved during an actual thermal therapy treatment session in a clinical trial according to a second variation of the control method of the present invention.
- anesthesia was used to ensure that the patients remained comfortable, so the patient comfort adaptability of the present invention was not utilized in the trial.
- Curve 190 represents the temperature of the catheter inserted into the urethra of the patient.
- Curve 192 represents the temperature of the coolant circulated between the antenna in the catheter and the urethral wall.
- Curve 194 represents the microwave power level delivered to the antenna.
- Curve 198 represents the temperature of tissue at a depth of approximately 0.5 cm in the prostate surrounding the urethra.
- the decrease in coolant temperature was set by the physician as the coolant temperature ramp rate (block 132, FIG. 7A ); the function utilized was a unit step function causing coolant to decrease in temperature as quickly as the heating/cooling system would allow, but again, the ramp rate and ramping function can vary as described above.
- the temperature of prostate tissue (curve 188) increased in a manner corresponding to the coolant temperature decrease.
- Coolant temperature finally reached a steady-state temperature, which again had been set by the physician at block 132, FIG. 7A .
- rectal temperature was monitored to ensure that temperatures do not exceed a predetermined threshold, to prevent thermal damage to the rectum; no excessively high rectal temperatures were detected.
- tissue temperatures exceeding about 90% of the peak tissue temperature were obtained within about 10 minutes.
- FIGS. 8A and 8B are exemplary, and the particular temperatures chosen and observed in practicing the present invention will vary depending on the patient's comfort level, the particular catheter structure utilized, and otherfactors.
- the thermal therapy control method of the present invention is significant different from prior art control methods, in that the therapy is driven by controlling coolant temperature and making automatic corresponding adjustments to microwave power to maintain catheter or tissue temperature at a particular set point.
- coolant temperature is preferably as low as possible, so that microwave power is forced to correspondingly increase to maintain cathetertemperature constant and tissue is therefore heated to maximum temperatures.
- Rectal temperature is one factor that limits the therapy, since the rectum must be preserved below a threshold temperature to avoid thermal damage.
- the control method of the present invention allows the thermal therapy system to be optimally operated, with rectal temperatures as high as possible without thermally damaging the rectum and catheter temperatures maintained at a predetermined steady-state operating temperature.
- the thermal therapy control method of the present invention has been described primarily as it applies to treatment of a prostate from a urethra. However, the principles and methods of the present invention are likewise applicable to thermally treating other regions of tissue from adjacent body cavities. Preservation of adjacent organs may also be applicable, in a manner similar to the preservation of the rectum described above with respect to one preferred embodiment of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Electromagnetism (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Description
- The present invention relates to a thermal therapy system for treating tissue such as the prostate with enhanced treatment effectiveness and minimal treatment time.
- The prostate gland is a complex, chestnut-shaped organ which encircles the urethra immediately below the bladder. Nearly one third of the prostate tissue anterior to the urethra consists of fibromuscular tissue that is anatomically and functionally related to the urethra and the bladder. The remaining two thirds of the prostate is generally posterior to the urethra and is comprised of glandular tissue. The portion of the urethra extending through the prostate (i.e., the prostatic urethra) includes a proximal segment, which communicates with the bladder, and a distal segment, which extends at an angle relative to the proximal segment by the verumontanum.
- Although a relatively small organ, the prostate is the most frequently diseased of all internal organs and is often the site of a common affliction among older men, benign prostatic hyperplasia (BPH), as well as a more serious affliction, cancer. BPH is a nonmalignant, bilateral expansion of prostate tissue occurring mainly in the transition zone of the prostate adjacent to the proximal segment of the prostatic urethra. As this tissue grows in volume, it encroaches on the urethra extending into the region of the bladder neck at the base of the bladder. Left untreated, BPH causes obstruction of the urethra which usually results in increased urinary frequency, urgency; incontinence, nocturia and slow or interrupted urinary stream. BPH may also result in more severe complications, such as urinary tract infection, acute urinary retention, hydronephrosis and uraemia.
- Benign prostatic hyperplasia (BPH) may be treated using transurethral thermal therapy as described in further detail in
U.S. Patent 5,620,480 entitled METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA WITH THERMAL THERAPY and inU.S. Patent 5,575,811 entitled BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING, During transurethral thermal therapy, the transition zone of the prostate is heated to necrose the tumorous tissue that encroaches on the urethra. Transurethral thermal therapy is administered by use of a microwave antenna-containing catheter which includes a multi-lumen shaft. The catheter is positioned in the urethra with the microwave antenna located adjacent to the hyperplastic prostatic tissue. Energization of the microwave antenna causes the antenna to emit electromagnetic energy which heats tissue within the prostate. A cooling fluid is circulated through the catheter to preserve tissue such as the urethral wall between the microwave antenna and the target tissue of the prostate.US 5 755 754 discloses the system of the preamble of appendedclaim 1. - The primary goal of transurethral thermal therapy is to necrose prostate tissue while preserving adjacent healthy tissue. It is also preferable to achieve this goal in as short of a time as is possible, consistent with the patient's level of tolerance and comfort. In addition, it is important that the rectum be preserved from unduly high temperatures, since it is susceptible to thermal damage. There is an ongoing need in the art for a method of controlling thermal therapy that reduces treatment time and enhances effectiveness consistent with all of these parameters.
- The present invention is a thermal therapy system for treating tissue with heat from an adjacent body cavity, such as treating a prostate with heat delivered from a urethra as defined in appended
claim 1. An applicator is insertable into the body cavity, and includes a microwave antenna and at least one cooling fluid chamber for circulating a coolant between the microwave antenna and a wall of a body cavity in which the applicator is capable of insertion. A microwave generator is operable to energize the microwave antenna in the applicator, and a coolant temperature controller is operable to control a temperature of the coolant circulating between the microwave antenna and the wall of the body cavity. A control system selectively operates the microwave generator and the coolant temperature controller to adjust the temperature of the coolant according to a predetermined coolant temperature profile, continually adjust coolant temperature based on therapy parameters, and maintain the applicator at a temperature corresponding to a predetermined applicator temperature profile by controlling the temperature of the coolant in coordination with a power level provided to the microwave antenna. In one exemplary embodiment, where the targeted tissue region is the prostate adjacent the urethra, rectal temperature is monitored and, upon sensing a predetermined rectal temperature profile, coolant temperature is adjusted. Coolant temperature may also be adjusted based on patient comfort indicators. The applicator is maintained at a temperature corresponding to a predetermined applicator temperature profile by adjusting a power level provided to the microwave antenna. -
-
FIG. 1 is a vertical section view of a male pelvic region showing the urinary organs affected by benign prostatic hyperplasia. -
FIG. 2 is an enlarged view of the male pelvic region ofFIG. 1 showing a urethral catheter positioned in the prostatic region. -
FIG. 3 is a cross-sectional view of a first exemplary urethral catheter. -
FIG. 4 is a cross-sectional view of a second exemplary urethral catheter. -
FIG. 5 is a block diagram of an exemplary transurethral microwave thermal therapy control system. -
FIGS. 6A and6B are graphs illustrating basic tissue temperature/depth curves at different power levels and coolant temperatures during thermal therapy. -
FIGS. 7A and7B are block diagrams illustrating the thermal therapy control methods according to two embodiments of the present invention. -
FIG. 8A is a graph illustrating temperatures achieved during a thermal therapy treatment session according to one variation of the control method of the present invention. -
FIG. 8B is a graph illustrating temperatures achieved during a thermal therapy treatment session according to a second variation of the control method of the present invention. - -
FIG. 1 is a vertical sectional view of a male pelvic region showing the effect benign prostatic hyperplasia (BPH) has on the urinary organs. Urethra 10 is a duct leading frombladder 12, throughprostate 14 and outorifice 16 ofpenis end 18. Benign tumorous tissue growth withinprostate 14 aroundurethra 10 causesconstriction 20 ofurethra 10, which interrupts the flow of urine fromneck 22 ofbladder 12 to orifice 16. The tumorous tissue ofprostate 14 which encroachesurethra 10 and causesconstriction 20 can be effectively removed by heating and necrosing the encroaching tumorous tissue. Ideally, periurethral tumorous tissue ofprostate 14 anterior and lateral tourethra 10 is heated and necrosed to avoid unnecessary and undesirous damage tourethra 10 and to adjacent healthy tissues, such asejaculatory duct 24 andrectum 26. A selective heating of benign tumorous tissue of prostate 14 (transurethral thermal therapy) may be achieved by utilizing a microwave antenna-containing catheter such as is shown inU.S. Patent 5,620,480 orU.S. Patent 5,575,811 . -
FIG. 2 shows an enlarged view of the male pelvic region ofFIG. 1 with acatheter 27 simplistically shown properly positioned withinurethra 10. While the particular structure ofcatheter 27 may vary and a number of lumens may be provided therein,catheter 27 typically includestransmission line 28 connected tomicrowave antenna 30 for emitting microwave energy toprostate 14. Cooling fluid is circulated alongpaths 32 betweenmicrowave antenna 30 and thewalls 36 ofurethra 10, so as to conductively cool the tissue ofurethra 10 whenmicrowave antenna 30 is energized to radiate microwave energy toprostate 14.Catheter 27 may be secured withinurethra 10 byretention balloon 34 located inbladder 12, for example. The temperature of the urethra may be detected by providing a temperature sensor oncatheter 27 contactingurethral walls 36. In addition, the temperature ofrectum 26 may be detected by inflating a balloon or providing another type of device inrectum 26 that includes a temperature sensor in contact with the rectal wall, such as is disclosed inU.S. Patent 5,792,070 entitled RECTAL THERMOSENSING UNIT, (particular reference being made toFIG. 1 , which illustrates an inflated rectal thermosensing unit carrying a temperature sensor, and the accompanying description atcolumn 3, line 24 -column 5, line 42). -
FIG. 3 is a cross-sectional view of a first exemplaryurethral catheter 27a. As shown inFIG 3 ,urethral catheter 27a includesridges 38,sleeve 40, outerthermal sensing lumen 41,apertures chamber 43,microwave antenna lumen 44,urine drainage lumen 46, coolantfluid return lumen 48,inflation lumen 52, innerthermal sensing lumen 54,fluid channels antenna jacket 61, and coolantfluid supply shaft 63. Outerthermal sensing lumen 41 and innerthermal sensing lumen 54 contain a thermal sensor which monitors the temperature ofurethra 10 during therapy.Antenna jacket 61 securely contains a microwave antenna (not shown inFIG. 3 ) during therapy. -
Fluid channel 60 provides a supply path for the cooling fluid between coolantfluid supply shaft 63 andchamber 43 whilefluid channel 58 provides a return path for the cooling fluid betweenchamber 43 andlumen 48. The cooling fluid is circulated from coolantfluid supply shaft 63 intochamber 43 viaaperture 42B andfluid channel 60. The coolingfluid fills chamber 43 defined bycatheter shaft 33 andPET sleeve 40. The cooling fluid returns tocatheter shaft 33 through coolant fluid returnlumen 48 viaaperture 42A andfluid channel 58. -
FIG. 4 is a cross-sectional view of a second exemplaryurethral catheter 27b. Coolingfluid intake lumens first side 78 ofshaft 31 andantenna lumen 68. Coolingfluid intake lumens Intake lumens intake lumens lumens antenna lumen 68. This assists in controlling the volume of tissue adjacentfirst side 78 ofshaft 31 that is heated above about 45° C. Second, water withinlumens first side 78 from being overheated and damaged when the antenna is energized. - Cooling
fluid exhaust lumens second side 82 andantenna lumen 68. Likeintake lumens exhaust lumens Exhaust lumens intake lumens intake lumens exhaust lumens second side 82 will remain below about 45° C. Water withinexhaust lumens second side 82 from being overheated and damaged when the antenna is energized. -
FIG. 5 is a block diagram of an exemplary transurethral microwavethermal therapy system 92, with whichurethral catheter 27 is used.System 92 includescooling system 86,microwave generating source 84,user interface 94, real time controller (RTC) 96,directional coupler 100,thermometry sensors coolant pressure sensor 114,balloon inflation device 110, andurine collection container 112. - As shown in
FIG. 5 , control ofmicrowave generating source 84 andcooling system 86 is effected by RTC 96, which is in turn controlled byuser interface 94. In one preferred embodiment,user interface 94 is an IBM compatible machine containing two hard drives for data storage: one for backup, and one for normal operation ofsystem 92.User interface 94 communicates with RTC 96, which is responsible for closed-loop feedback to runsystem 92. RTC 96 has direct closed-loop control of microwave power frommicrowave generating source 84, and coolant flow and coolant temperature of coolingsystem 86. The closed-loop feedback of RTC 96 tracks out variations in gain, drift and cable losses inherent inmicrowave generating source 84. RTC 96 also tracks the variability in pump output and refrigeration system efficiency of coolingsystem 86. In addition to monitoringmicrowave generation source 84 andcooling system 86, RTC 96 also monitors and controls several channels of thermometry via inputs fromthermometry unit 98. Cooling system thermometry 98A measures the coolant and chiller temperatures based upon signals from coolingtemperature sensor cooling system 86.Urethral thermometry 98B measures urethral temperature based upon signals from a temperature sensor withincatheter 27.Rectal thermometry 98C measures rectal temperature based upon signals received from a sensor (not shown) withinrectal probe 108. - RTC 96 transmits closed-loop feedback to
user interface 94, which processes the input and transmits corrections and instructions back to RTC 96. RTC 96 interprets the instructions given to it by process control language received fromuser interface 94 and executes the instructions in real time. Corrections fromuser interface 94 are made to maintain a desired thermal profile throughout the transurethral thermal therapy. In addition,system 92 includes a hardware fail-safe circuit which shuts downsystem 92 should any parameter fall outside a given range of values. -
FIGS. 6A and6B are graphs illustrating basic tissue temperature/depth curves at different power levels and coolant temperatures during thermal therapy, and demonstrating the basic principles of the present invention. Particularity,FIG. 6A illustrates tissue temperature/depth curves for a treatment session where catheter temperature is held at a predetermined value (such as 40°C), andFIG. 6B illustrates tissue temperature/depth curves for a treatment session where a certain depth of tissue around the catheter is held at a predetermined value (such as 40°C). The vertical axes ofFIGS. 6A and6B represent the temperature of tissue, and the horizontal axes represent the depth from the catheter/urethra of that tissue. Therefore, a depth of zero represents the urethral wall. - Each of the curves shown in
FIG. 6A represents a different coolant temperature and microwave power condition, with the constant criteria for each curve being that the temperature of the catheter (at depth=0) is maintained at a steady-state temperature such as 40°C. Curve 120 represents a situation where microwave power is zero and coolant temperature is equal to the steady-state catheter temperature (e.g., 40°C),curve 122 represents a situation where the microwave power is high and coolant temperature is at a minimum (such as 8°C, for illustrative purposes) and the curves betweencurve 120 andcurve 122 represent situations where the microwave power is between zero and the high value, and the coolant temperature is between the steady-state catheter temperature (e.g., 40°C) and (the minimum coolant temperature (e.g., 8°C). Each curve is labeled according to the relative coolant temperature (tc) and power level (p), so thatcurve 120 represents the highest coolant temperature (tc1) and the lowest power (p7) andcurve 122 represents the lowest coolant temperature (tc7) and the highest power level (p1), wherein each curve is predicated on the condition that catheter temperature is maintained at a steady-state temperature such as 40°C. The particular values of the minimum coolant temperature and corresponding power level depend on -the structure and characteristics of the treatment catheter employed, and it should be understood that the exemplary values provided herein refer only to one particular catheter structure; othervalues are appropriate for different catheter structures, while still practicing the present invention. As can be seen from the curves shown inFIG. 6A , when the catheter temperature is maintained at a steady-state temperature such as 40°C, decreased coolant temperature results in deeper heating of tissue in the prostate due to the increased power level required to maintain the catheter at the steady-state temperature. This may result in a greater depth of necrosis caused by heating the tissue above a particular threshold temperature. - Each of the curves shown in
FIG. 6B also represent a different coolant temperature and microwave power condition, with the constant criteria for each curve being that the temperature of tissue at a depth of interest, defining a zone of protection from the outer surface of the catheter to that tissue depth (such as 1 millimeter, for example), is maintained at a steady-state temperature such as 40°C. Curve 124 represents a situation where microwave power is slightly greater than zero and coolant temperature is equal to a temperature slightly greater than the steady-state tissue temperature (e.g., 40°C), which is slightly different from the power and coolant temperature shown in curve 120 (FIG. 6A ) where the catheter rather than a depth of tissue was maintained at a steady-state temperature such as 40°C. Curve 126 represents a situation where the microwave power is high and coolant temperature is at a minimum (such as 8°C, for illustrative purposes) and the curves between curve 124 andcurve 126 represent situations where the microwave power is between zero, and the high value, and the coolant temperature is between the steady-state tissue temperature (e.g., 40°C) and the minimum coolant temperature (e.g., 8°C). Each curve is labeled according to the relative coolant temperature (tc) and power level (p), so that curve 124 represents the highest coolant temperature (tc1) and the lowest power (p7) andcurve 126 represents the lowest coolant temperature (tc7) and the highest power level (p1), wherein each curve is predicated on the condition that tissue temperature is maintained at a steady-state temperature such as 40°C. The particular values of the minimum coolant temperature and corresponding power level depend on the structure and characteristics of the treatment catheter employed, and it should be understood that the exemplary values provided herein refer only to one particular catheter structure; other values are appropriate for different catheter structures, while still practicing the present invention. As can be seen from the curves shown inFIG. 6b , when the tissue temperature at a depth of interest is maintained at a steady-state temperature such as 40°C, decreased coolant temperature results in deeper heating of tissue in the prostate due to the increased power level required to maintain the tissue at the steady-state temperature. This may result in a greater depth of necrosis caused by heating the prostate tissue above a particular threshold temperature. - In the thermal therapy curves depicted in
FIGS. 6A and6B , if coolant temperature is continually decreased and microwave power is correspondingly continually increased to maintain the catheter or tissue temperature at the steady-state temperature or at a set point temperature while initially ramping up the catheter/tissue temperature, temperatures at the depth of the rectum may become unacceptably high. In other words, high temperatures are achieved at too great of a depth from the catheter/urethra. Therefore, in a preferred method of controlling thermal therapy, rectal temperature is utilized as a parameter for controlling the coolant temperature (and the catheter/tissue temperature set point, temporarily) to enable optimal therapy without thermally damaging the tissue of the rectum. -
FIG. 7A is a block diagram illustrating a complete thermal therapy control method according to a first embodiment of the present invention, utilizing the principles and parameters discussed above with respect toFIG. 6A . To initialize the therapy, a physician enters inputs related to catheter temperature atblock 130a and inputs related to coolant temperature atblock 132. Specifically, a physician enters an initial ramp rate of catheter temperature (that is, how quickly and in what manner the catheter temperature is to increase from its initial temperature of approximately body temperature (37°C) to its final, steady-state temperature) and a steady-state catheter temperature. In addition, the physician enters a coolant temperature ramp rate (that is, how quickly and in what manner the coolant temperature is to decrease from its initial temperature to a targeted final temperature), an initial coolant temperature and a steady-state coolant temperature. The catheter temperature ramp rate and the coolant temperature ramp rate may comprise a ramping function, such that cathetertemperature and/or coolant temperature increases or decreases exponentially, linearly, or according to some other function that enhances the effectiveness of the therapy consistent with patient comfort concerns. The exact value and degree of physician contribution of these inputs will depend on experimental results of therapy in particular patients, and are set consistent with a desired patient comfort level. The actual format of physician input may also be simplified by an appropriate software program or other means, so that the physician enters only minimal data and the program calculates the therapy inputs from the data entered by the physician. The physician inputs are further explained graphically below with respect toFIGS. 8A and8B . - From the catheter temperature inputs entered at block 130, a catheter temperature profile is established at block 138. The catheter temperature profile represents a desired characteristic of catheter temperature at a particular time in the thermal therapy session, which may of course be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below. From the coolant temperature inputs entered at
block 132. a coolant temperature profile is established atblock 134. The coolant temperature profile also represents a desired characteristic of coolant temperature at a particular time in the thermal therapy session, which again may be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below. - The catheter temperature profile signal is passed on to adder/
subtractor 136, which passes a modified cathetertemperature set point signal on to Microwave Power Control block 140, which in one preferred embodiment is implemented as a proportional/integrat/differential (PID) control loop. PID control loops are algorithms known in the art for controlling a process to achieve a desired output level. The power delivered to the microwave antenna 30 (FIG. 2 ) energizes the antenna to radiate electromagnetic energy, resulting in elevation of prostate tissue temperature as represented byblock 142. Power delivered to the microwave antenna is continually adjusted to ensure that the catheter remains at the modified catheter temperature set point; therefore, Microwave Power Control block 140 is responsive to the measured catheter temperature atblock 148 to adjust microwave power accordingly. - Elevation of prostate tissue temperature at
block 142 causes a biological response in the tissue, which is represented byblock 144. One response is increased blood perfusion in the tissue, which tends to conduct heat away from a particular portion of tissue and reduce the heating effect on the tissue. Also, when electromagnetic energy is delivered to elevate the temperature of prostate tissue, the temperature of the rectum may also be increased. Rectal temperatures are therefore monitored during thermal therapy to ensure that the rectum is not thermally damaged by excessively high temperatures; the measured rectal temperature is represented byblock 146. If rectal temperature reaches a predetermined threshold, steps must be taken to reduce the temperature of the rectum so that it may be preserved. In an ideal situation, coolant temperature would be immediately increased (with microwave power correspondingly decreased to maintain catheter temperature at the desired set point) in response to high rectal temperatures. However, in actuality, it may not be possible to instantaneously change the temperature of the coolant. Therefore, to safely ensure preservation of the rectum, according to one preferred embodiment of the present invention, the catheter temperature is initially reduced in response to high rectal temperatures by a catheter temperature modifier represented at block 150. The catheter temperature modifier is subtracted by adder/subtractor 136 from the desired catheter temperature provided by the catheter temperature profile to yield a modified catheter temperature set point, which is input to Microwave Power Control block 140. By reducing the catheter temperature set point immediately, with all other parameters remaining the same, the microwave power will be reduced and tissue temperatures will immediately decrease. For increasingly higher rectal temperatures, the catheter temperature set point is decreased by a greater amount. In addition, a CoolantTemperature Control block 152 implements a PID control loop, for example, to determine an increased temperature of the coolant.Comparator block 154 outputs the higher of the coolant temperature provided by the coolant temperature profile atblock 134 and the coolant temperature provided by CoolantTemperature Control block 152. In other words, the desired coolant temperature is determined by the coolant temperature profile atblock 134 unless an excessively high rectal temperature causes a higher coolant temperature to be determined by CoolantTemperature Control block 152. The desired coolant temperature is input to Cooler/Heater Control block 156 along with the measured coolant temperature atblock 160, and Cooler/Heater Control block 156 implements a PID control loop, for example, to adjust coolant temperature and stabilize the coolant at the appropriate temperature. The actual coolant temperature affects the temperature of the catheter and temperature to which prostate tissue and the rectum are elevated, which is represented by the line from Cooler/Heater Control block 156 to the tissue temperature elevation shown atblock 142. Finally, as the rectal temperature returns to a value below the threshold, the catheter temperature modifier is reduced to zero, and the catheter temperature returns to the value provided by the catheter temperature profile at block 138, with the system stabilizing at the higher coolant temperature. By implementing this control method, rectal temperatures (and prostate tissue temperatures) reach the highest attainable level without exceeding a threshold rectal temperature, while simultaneously maintaining the catheter temperatu re set point at the maximum desired value consistent with patient comfort. It is somewhat counter-intuitive that coolant temperature should be increased in response to excessively high temperatures in the rectum, but it is nonetheless true where the catheter temperature is constrained to a predetermined steady-state value, since an increase in coolant temperature effectively forces a reduction in power provided to the microwave antenna to maintain the catheter at the steady-state value. The method of the present invention therefore enhances the effectiveness and reduces the necessary treatment time of the therapy. - The thermal therapy controlled by the method of the present invention must take into account the comfort level of the patient at various phases of the therapy. For example, the catheter temperature ramp rate or ramping function or the steady-state catheter temperature may potentially drive changes in power that may result in discomfort for the patient. Similarly, the coolant temperature ramp rate or ramping function or other parameters may also result in power level changes that could potentially cause some patient discomfort. As the thermal therapy session progresses, a physician may adjust the therapy at any time in response to an indication of patient discomfort, represented by
block 158. Patient discomfort may potentially occur as a result of high absolute temperatures, or also as a result of high rates of change of temperatures, and therapy therefore is adjustable to change parameters related to both of these factors. The therapy parameter changes implemented by the physician (at blocks 130 and 132) are integrated into the therapy control method of the present invention to reduce or eliminate the discomfort of the patient. -
FIG. 7B is a block diagram illustrating a complete thermal therapy control method according to a second embodiment of the present invention, utilizing the principles and parameters discussed above with respect toFIG. 6B . The majority of the method shown inFIG. 7B is identical to that shown inFIG. 7A , with one principal modification. Instead of utilizing a catheter temperature set point as shown inFIG. 7A , the modified method shown inFIG. 7B is concerned with a tissue temperature set point (that is, the temperature in tissue at some depth of interest from the catheter/urethra, defining a tissue protection zone). Therefore, to initialize the therapy, a physician enters an initial tissue temperature ramp rate/ramping function and a steady-state tissue temperature atblock 130b, in a manner substantially similar to that described with respect to block 130a ofFIG. 7A . From the tissue temperature inputs entered atblock 130b, a tissue temperature profile is established atblock 138b, which represents a desired characteristic of tissue temperature at a particular time in the thermal therapy session, which may of course be adjusted by other parameters such as rectal temperature and patient comfort during the course of the therapy, as noted below. - The tissue temperature profile signal is passed on to adder/
subtractor 136, which passes a modified tissue temperature set point signal on to Microwave Power Control block 140, which is implemented as described above with respect toFIG. 7A . The power delivered to microwave antenna 30 (FIG. 2 ) energizes the antenna to radiate electromagnetic energy, resulting in elevation of prostate tissue as represented byblock 142. Power delivered to the microwave antenna is continually adjusted to ensure that tissue at the depth of interest remains at the modified tissue temperature set point. In order to do so, Microwave Power Control block 140 must be responsive to tissue temperature. However, tissue temperature at a depth from the catheter/urethra typically cannot be measured directly without penetrating the urethra. Therefore, in one embodiment of the present invention, catheter temperature is measured atblock 148, and tissue temperature is calculated atblock 149 based on the measured catheter temperature (block 148), the microwave power level (block 140) and the measured coolant temperature (block 160). Microwave Power Control block 140 is therefore responsive to the calculated tissue temperature atblock 149 to adjust microwave power accordingly. In an alternative embodiment, a temperature sensor may be positioned in the tissue by penetrating the urethra, or some other temperature sensing system for directly measuring tissue temperature may be implemented, in which case the measured tissue temperature would replace measured catheter temperature atblock 148 ofFIG. 7A , and there would be no need to calculate tissue temperature. - Rectal temperatures are also monitored during thermal therapy to ensure that the rectum is not thermally damaged by excessively high temperatures; the measured rectal temperature is represented by
block 146. If rectal temperature reaches a predetermined threshold, steps must be taken to reduce the temperature of the rectum so that it may be preserved. As described above with respect toFIG. 7A , since coolant temperature may not be able to be instantaneously increased, the temperature set point is initially decreased to force microwave power to be immediately reduced. This tissue temperature set point is reduced by the tissue temperature modifier represented atblock 150b, which is subtracted by adder/subtractor 136 from the desired tissue temperature to yield a modified tissue temperature set point input to Microwave Power Control block 140. As also described above with respect toFIG. 7A , after coolant temperature is increased and rectal temperature is returning to a value below the threshold, the tissue temperature modifier is reduced to zero, and the tissue temperature returns to the value provided by the tissue temperature profile atblock 138b, with the system stabilizing at the higher coolant temperature. -
FIG. 8A is a graph illustrating measured temperatures achieved during an actual thermal therapy treatment session in a clinical trial according to one variation of the control method of the present invention. In the clinical trial, anesthesia was used to ensure that the patients remained comfortable, so the patient comfort adaptability of the present invention was not utilized in the trial.Curve 180 represents the temperature of the catheter inserted into the urethra of the patient.Curve 182 represents the temperature of the coolant circulated between the antenna in the catheter and the urethral wall; the small oscillations incurve 182 are due to the heating/cooling system utilized in the trial.Curve 184 represents the microwave power level delivered to the antenna.Curve 188 represents the temperature of tissue at a depth of approximately 0.5 cm in the prostate surrounding the urethra. - Initially, power (curve 184) was ramped up quickly to raise the temperature of the catheter (curve 180) to approximately 40°C (the catheter temperature set point), with coolant temperature (curve 182) at an initial value of approximately 22°C. These characteristics correspond to the catheter temperature ramp rate and the initial coolant temperature set by the physician at
blocks 130a and 132 (FIG. 7A ). The ramp rate and ramping function may vary as described above; the clinical trial shown inFIG. 8A utilized a unit step function, which increased catheter temperature to the steady-state value as quickly as the system capabilities permitted. Coolant temperature was then reduced in step-wise increments, while the microwave power level was increased in turn to maintain the catheter temperature at the steady-state temperature such as 40°C (set by the physician inblock 130a,FIG. 7A ). The step-wise decrease in coolant temperature was set by the physician as the coolanttemperature ramp rate (block 132,FIG. 7A ); again, the ramp rate and ramping function can vary as described above. As a result, the temperature of prostate tissue (curve 188) increased in a corresponding step-wise manner to the coolant temperature decrease. Coolant temperature finally reached a steady-state temperature, which again had been set by the physician atblock 132,FIG. 7A . Also, throughout the therapy, rectal temperature was monitored to ensure that temperatures do not exceed a predetermined threshold, to prevent thermal damage to the rectum; no excessively high rectal temperatures were detected. - At a treatment time between 30 and 40 minutes, the catheter temperature set point (curve 180) was increased from 40°C to 42°C for experimental purposes. As expected, the increase in steady-state catheter temperature resulted in a corresponding increase in power (curve 184) and tissue temperature (curve 188), while the coolant temperature (curve 182) was kept constant.
-
Microwave power curve 184,catheter temperature curve 180 andtissue temperature curve 188 experience some oscillation at a treatment time between 40 and 50 minutes. These oscillations were due to a bladder spasm experienced by the patient at this time, which may occur from time to time during a thermal therapy treatment session. During the bladder spasm, although catheter temperature oscillated briefly, the control method of the present invention caused it to remain at a level approximately equal to or below the catheter temperature set point, and catheter temperature returned to the steady-state temperature automatically and stabilized with no outside intervention when the bladder spasm ceased. -
FIG. 8B is a graph illustrating measured temperatures achieved during an actual thermal therapy treatment session in a clinical trial according to a second variation of the control method of the present invention. In the clinical trial, anesthesia was used to ensure that the patients remained comfortable, so the patient comfort adaptability of the present invention was not utilized in the trial.Curve 190 represents the temperature of the catheter inserted into the urethra of the patient.Curve 192 represents the temperature of the coolant circulated between the antenna in the catheter and the urethral wall.Curve 194 represents the microwave power level delivered to the antenna.Curve 198 represents the temperature of tissue at a depth of approximately 0.5 cm in the prostate surrounding the urethra. - Initially, power (curve 194) was ramped up quickly to raise the temperature of the catheter (curve 190) to approximately 40°C (the catheter temperature set point), with coolant temperature (curve 192) at an initial value of approximately 28°C. These characteristics correspond to the catheter temperature ramp rate and the initial coolant temperature set by the physician at
blocks 130a and 132 (FIG. 7A ). The ramp rate and ramping function may vary as described above; the clinical trial shown inFIG. 8B utilized a unit step function, which increased catheter temperature to the steady-state value as quickly as the system capabilities permitted. Coolant temperature was then reduced quickly, while the microwave power level was increased in turn to maintain the catheter temperature at the steady-state temperature such as 40°C (set by the physician inblock 130a,FIG. 7A ). The decrease in coolant temperature was set by the physician as the coolant temperature ramp rate (block 132,FIG. 7A ); the function utilized was a unit step function causing coolant to decrease in temperature as quickly as the heating/cooling system would allow, but again, the ramp rate and ramping function can vary as described above. As a result, the temperature of prostate tissue (curve 188) increased in a manner corresponding to the coolant temperature decrease. Coolant temperature finally reached a steady-state temperature, which again had been set by the physician atblock 132,FIG. 7A . Also, throughout the therapy, rectal temperature was monitored to ensure that temperatures do not exceed a predetermined threshold, to prevent thermal damage to the rectum; no excessively high rectal temperatures were detected. As can be seen inFIG. 8B , tissue temperatures exceeding about 90% of the peak tissue temperature were obtained within about 10 minutes. - It should be understood that the particular temperatures set and observed in the clinical trials illustrated by
FIGS. 8A and8B are exemplary, and the particular temperatures chosen and observed in practicing the present invention will vary depending on the patient's comfort level, the particular catheter structure utilized, and otherfactors. - The thermal therapy control method of the present invention is significant different from prior art control methods, in that the therapy is driven by controlling coolant temperature and making automatic corresponding adjustments to microwave power to maintain catheter or tissue temperature at a particular set point. In the absence of limiting parameters, coolant temperature is preferably as low as possible, so that microwave power is forced to correspondingly increase to maintain cathetertemperature constant and tissue is therefore heated to maximum temperatures. Rectal temperature is one factor that limits the therapy, since the rectum must be preserved below a threshold temperature to avoid thermal damage. The control method of the present invention allows the thermal therapy system to be optimally operated, with rectal temperatures as high as possible without thermally damaging the rectum and catheter temperatures maintained at a predetermined steady-state operating temperature. As a result, a precise depth of tissue necrosis is achievable with no physician intervention to control the therapy. Therapy times are also minimized, since the control method of the present invention allows tissue temperatures to reach 90% of their maximum value within about 10 minutes, if tolerable by the patient, which is a significant improvement over the prior art.
- The thermal therapy control method of the present invention has been described primarily as it applies to treatment of a prostate from a urethra. However, the principles and methods of the present invention are likewise applicable to thermally treating other regions of tissue from adjacent body cavities. Preservation of adjacent organs may also be applicable, in a manner similar to the preservation of the rectum described above with respect to one preferred embodiment of the invention.
- Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the scope of the invention.
Claims (6)
- A thermal therapy system comprising:an applicator insertable into a urethra adjacent a targeted tissue region of prostate tissue, the applicator including a microwave antenna and at least one cooling fluid chamber for circulating a coolant between the microwave antenna and a wall of the urethra;a rectal temperature sensing probe insertable into a rectum;a microwave generator operable to energize the microwave antenna in the applicator;a coolant temperature controller operable to control a
temperature of the coolant circulating between the microwave antenna and the wall of the urethra; anda control system for selectively operating the microwave generator and the coolant temperature controller to decrease the temperature of the coolant to a steady-state coolant temperature, maintain selected tissue at a predetermined depth from the wall of the urethra at a temperature corresponding to a predetermined tissue temperature profile, characterized in that the control system is further configured for operating the microwave generator and the coolant temperature controller to increase the coolant temperature in response to detection of a predetermined rectal temperature profile so as to force a reduction in power provided by the microwave generator to the microwave antenna to maintain the selected tissue at a temperature corresponding to the predetermined tissue temperature profile. - The thermal therapy system of claim 1, further comprising means for permitting a physician to input the predetermined tissue temperature profile and the steady-state coolant temperature.
- The thermal therapy system of claim 1, wherein the predetermined tissue temperature profile is a constant temperature of about 40°C.
- The thermal therapy system of any of claims 1 to 3, further comprising means for permitting a physician to input a catheter temperature ramp rate, an initial coolant temperature and a coolant temperature ramp rate.
- The thermal therapy system of any of claims 1 to 4, wherein the control system is operable to adjust at least one of the predetermined tissue temperature profile, the steady-state coolant temperature, the catheter temperature ramp rate, the initial coolant temperature and the coolant temperature ramp rate in response to patient comfort indicators.
- The thermal therapy system of any of claims 1 to 5, wherein the control system is operable to temporarily decrease the temperature of the selected tissue from the predetermined tissue temperature profile upon detecting the predetermined rectal temperature profile.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US210033 | 1998-12-11 | ||
US09/210,033 US6122551A (en) | 1998-12-11 | 1998-12-11 | Method of controlling thermal therapy |
PCT/US1999/029381 WO2000033767A1 (en) | 1998-12-11 | 1999-12-10 | Method of controlling thermal therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1148837A1 EP1148837A1 (en) | 2001-10-31 |
EP1148837A4 EP1148837A4 (en) | 2009-03-11 |
EP1148837B1 true EP1148837B1 (en) | 2012-09-26 |
Family
ID=22781331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99965224A Expired - Lifetime EP1148837B1 (en) | 1998-12-11 | 1999-12-10 | System for controlling thermal therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US6122551A (en) |
EP (1) | EP1148837B1 (en) |
JP (1) | JP2002531218A (en) |
AU (1) | AU762862B2 (en) |
CA (1) | CA2354587A1 (en) |
WO (1) | WO2000033767A1 (en) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6216703B1 (en) * | 1998-05-08 | 2001-04-17 | Thermatrx, Inc. | Therapeutic prostatic thermotherapy |
US6620189B1 (en) * | 2000-02-28 | 2003-09-16 | Radiant Medical, Inc. | Method and system for control of a patient's body temperature by way of a transluminally insertable heat exchange catheter |
US6122551A (en) * | 1998-12-11 | 2000-09-19 | Urologix, Inc. | Method of controlling thermal therapy |
US6019783A (en) * | 1999-03-02 | 2000-02-01 | Alsius Corporation | Cooling system for therapeutic catheter |
US6161049A (en) | 1999-03-26 | 2000-12-12 | Urologix, Inc. | Thermal therapy catheter |
US6272384B1 (en) * | 1999-05-27 | 2001-08-07 | Urologix, Inc. | Microwave therapy apparatus |
US6306132B1 (en) * | 1999-06-17 | 2001-10-23 | Vivant Medical | Modular biopsy and microwave ablation needle delivery apparatus adapted to in situ assembly and method of use |
US6312391B1 (en) * | 2000-02-16 | 2001-11-06 | Urologix, Inc. | Thermodynamic modeling of tissue treatment procedure |
US6477426B1 (en) * | 2000-06-20 | 2002-11-05 | Celsion Corporation | System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors |
AU2016204932B2 (en) * | 2000-07-21 | 2019-04-04 | Zoll Circulation, Inc. | Heat exchanger catheter for controlling body temperature |
US6530945B1 (en) * | 2000-11-28 | 2003-03-11 | Alsius Corporation | System and method for controlling patient temperature |
US6641602B2 (en) | 2001-04-13 | 2003-11-04 | Alsius Corporation | Method and device including a colo-rectal heat exchanger |
US7128739B2 (en) | 2001-11-02 | 2006-10-31 | Vivant Medical, Inc. | High-strength microwave antenna assemblies and methods of use |
US6878147B2 (en) | 2001-11-02 | 2005-04-12 | Vivant Medical, Inc. | High-strength microwave antenna assemblies |
US7197363B2 (en) | 2002-04-16 | 2007-03-27 | Vivant Medical, Inc. | Microwave antenna having a curved configuration |
US6752767B2 (en) | 2002-04-16 | 2004-06-22 | Vivant Medical, Inc. | Localization element with energized tip |
US7258688B1 (en) * | 2002-04-16 | 2007-08-21 | Baylis Medical Company Inc. | Computerized electrical signal generator |
US7722601B2 (en) | 2003-05-01 | 2010-05-25 | Covidien Ag | Method and system for programming and controlling an electrosurgical generator system |
US7311703B2 (en) * | 2003-07-18 | 2007-12-25 | Vivant Medical, Inc. | Devices and methods for cooling microwave antennas |
JP4504718B2 (en) * | 2004-03-31 | 2010-07-14 | テルモ株式会社 | Heat treatment device |
CN1298282C (en) * | 2004-09-09 | 2007-02-07 | 上海交通大学 | Device for controlling and measuring temperature on rectum wall |
US20070016272A1 (en) * | 2004-09-27 | 2007-01-18 | Thompson Russell B | Systems and methods for treating a hollow anatomical structure |
US8801701B2 (en) * | 2005-03-09 | 2014-08-12 | Sunnybrook Health Sciences Centre | Method and apparatus for obtaining quantitative temperature measurements in prostate and other tissue undergoing thermal therapy treatment |
US7771418B2 (en) * | 2005-03-09 | 2010-08-10 | Sunnybrook Health Sciences Centre | Treatment of diseased tissue using controlled ultrasonic heating |
US7799019B2 (en) | 2005-05-10 | 2010-09-21 | Vivant Medical, Inc. | Reinforced high strength microwave antenna |
US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
US7981146B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US20070060988A1 (en) * | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
US8950405B2 (en) * | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US7981095B2 (en) * | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
US8083787B2 (en) * | 2005-07-18 | 2011-12-27 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction |
US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
US20070055326A1 (en) | 2005-07-21 | 2007-03-08 | Farley Brian E | Method of treating a hollow anatomical structure with a thermal catheter |
US8123705B2 (en) * | 2005-10-06 | 2012-02-28 | Boston Scientific Scimed, Inc. | Adjustable profile probe |
US7981147B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US9314369B2 (en) * | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US8128674B2 (en) * | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8007524B2 (en) * | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US7976573B2 (en) * | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
FR2905277B1 (en) * | 2006-08-29 | 2009-04-17 | Centre Nat Rech Scient | DEVICE FOR THE VOLUMIC TREATMENT OF BIOLOGICAL TISSUES |
US8068921B2 (en) | 2006-09-29 | 2011-11-29 | Vivant Medical, Inc. | Microwave antenna assembly and method of using the same |
US7998139B2 (en) | 2007-04-25 | 2011-08-16 | Vivant Medical, Inc. | Cooled helical antenna for microwave ablation |
US8353901B2 (en) | 2007-05-22 | 2013-01-15 | Vivant Medical, Inc. | Energy delivery conduits for use with electrosurgical devices |
US9023024B2 (en) | 2007-06-20 | 2015-05-05 | Covidien Lp | Reflective power monitoring for microwave applications |
US9861424B2 (en) | 2007-07-11 | 2018-01-09 | Covidien Lp | Measurement and control systems and methods for electrosurgical procedures |
US8152800B2 (en) | 2007-07-30 | 2012-04-10 | Vivant Medical, Inc. | Electrosurgical systems and printed circuit boards for use therewith |
US7645142B2 (en) | 2007-09-05 | 2010-01-12 | Vivant Medical, Inc. | Electrical receptacle assembly |
US8747398B2 (en) | 2007-09-13 | 2014-06-10 | Covidien Lp | Frequency tuning in a microwave electrosurgical system |
US8651146B2 (en) | 2007-09-28 | 2014-02-18 | Covidien Lp | Cable stand-off |
US8409110B2 (en) * | 2007-10-05 | 2013-04-02 | Medifocus, Inc. | Thermal monitoring |
US8292880B2 (en) | 2007-11-27 | 2012-10-23 | Vivant Medical, Inc. | Targeted cooling of deployable microwave antenna |
US8414501B2 (en) | 2007-12-28 | 2013-04-09 | Medifocus, Inc. | Thermal monitoring |
USD617443S1 (en) | 2008-02-06 | 2010-06-08 | Tearscience, Inc. | Eye treatment goggles |
USD613408S1 (en) | 2008-02-06 | 2010-04-06 | Tearscience, Inc. | Eye treatment head gear |
AU2015203459B2 (en) * | 2008-03-31 | 2016-11-03 | Covidien Lp | Re-hydration antenna for ablation |
US9198723B2 (en) | 2008-03-31 | 2015-12-01 | Covidien Lp | Re-hydration antenna for ablation |
US20100016932A1 (en) * | 2008-07-15 | 2010-01-21 | Irving Weinberg | Apparatus and method for internal hypothermic radioprotection |
US20100087808A1 (en) * | 2008-10-03 | 2010-04-08 | Vivant Medical, Inc. | Combined Frequency Microwave Ablation System, Devices and Methods of Use |
PT2352453T (en) | 2008-11-06 | 2018-05-29 | Nxthera Inc | Systems and methods for treatment of prostatic tissue |
CN102271595A (en) | 2008-11-06 | 2011-12-07 | 恩克斯特拉公司 | Systems and methods for treatment of bph |
US8961577B2 (en) * | 2009-04-02 | 2015-02-24 | Julie Ann Reil | Correction of female urinary incontinence and skin reduction |
US20110245587A1 (en) * | 2010-04-05 | 2011-10-06 | Julie Ann Reil | Method for correction of female urinary incontinence and skin reduction |
US9833277B2 (en) | 2009-04-27 | 2017-12-05 | Nxthera, Inc. | Systems and methods for prostate treatment |
US8954161B2 (en) | 2012-06-01 | 2015-02-10 | Advanced Cardiac Therapeutics, Inc. | Systems and methods for radiometrically measuring temperature and detecting tissue contact prior to and during tissue ablation |
US9226791B2 (en) | 2012-03-12 | 2016-01-05 | Advanced Cardiac Therapeutics, Inc. | Systems for temperature-controlled ablation using radiometric feedback |
US9277961B2 (en) | 2009-06-12 | 2016-03-08 | Advanced Cardiac Therapeutics, Inc. | Systems and methods of radiometrically determining a hot-spot temperature of tissue being treated |
US8926605B2 (en) | 2012-02-07 | 2015-01-06 | Advanced Cardiac Therapeutics, Inc. | Systems and methods for radiometrically measuring temperature during tissue ablation |
US9113925B2 (en) * | 2009-09-09 | 2015-08-25 | Covidien Lp | System and method for performing an ablation procedure |
USD638128S1 (en) | 2009-10-06 | 2011-05-17 | Tearscience, Inc. | Ocular device design |
ES2714390T3 (en) | 2010-03-09 | 2019-05-28 | Profound Medical Inc | Ulttrasound therapy applicator |
US11027154B2 (en) | 2010-03-09 | 2021-06-08 | Profound Medical Inc. | Ultrasonic therapy applicator and method of determining position of ultrasonic transducers |
US9707413B2 (en) | 2010-03-09 | 2017-07-18 | Profound Medical Inc. | Controllable rotating ultrasound therapy applicator |
WO2011112251A1 (en) | 2010-03-09 | 2011-09-15 | Profound Medical Inc. | Fluid circuits for temperature control in a thermal therapy system |
WO2011115664A2 (en) * | 2010-03-14 | 2011-09-22 | Profound Medical Inc. | Mri-compatible motor and positioning system |
AU2011230568B2 (en) | 2010-03-25 | 2016-02-18 | Boston Scientific Scimed, Inc. | Systems and methods for prostate treatment |
CN106377312B (en) | 2010-10-25 | 2019-12-10 | 美敦力Af卢森堡有限责任公司 | Microwave catheter apparatus, systems, and methods for renal neuromodulation |
US9204922B2 (en) | 2010-12-01 | 2015-12-08 | Enable Urology, Llc | Method and apparatus for remodeling/profiling a tissue lumen, particularly in the urethral lumen in the prostate gland |
CN103917200B (en) | 2011-09-13 | 2016-03-30 | 恩克斯特拉公司 | For the system and method for prostate treatment |
WO2013152119A1 (en) | 2012-04-03 | 2013-10-10 | Nxthera, Inc. | Induction coil vapor generator |
WO2014031857A2 (en) | 2012-08-22 | 2014-02-27 | Tearscience, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
US9333035B2 (en) | 2012-09-19 | 2016-05-10 | Denervx LLC | Cooled microwave denervation |
CN105208939A (en) | 2013-03-14 | 2015-12-30 | 恩克斯特拉公司 | Systems and methods for treating prostate cancer |
ES2821002T3 (en) | 2013-04-30 | 2021-04-23 | Alcon Inc | Systems for the treatment of eye diseases |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
US10390881B2 (en) | 2013-10-25 | 2019-08-27 | Denervx LLC | Cooled microwave denervation catheter with insertion feature |
US9968395B2 (en) | 2013-12-10 | 2018-05-15 | Nxthera, Inc. | Systems and methods for treating the prostate |
JP6422975B2 (en) | 2013-12-10 | 2018-11-14 | エヌエックスセラ インコーポレイテッド | Steam ablation system and method |
US20150209107A1 (en) | 2014-01-24 | 2015-07-30 | Denervx LLC | Cooled microwave denervation catheter configuration |
JP6725178B2 (en) | 2014-11-19 | 2020-07-15 | エピックス セラピューティクス,インコーポレイテッド | Ablation apparatus, systems and methods using high resolution electrode assemblies |
JP6673598B2 (en) | 2014-11-19 | 2020-03-25 | エピックス セラピューティクス,インコーポレイテッド | High resolution mapping of tissue with pacing |
JP6825789B2 (en) | 2014-11-19 | 2021-02-03 | エピックス セラピューティクス,インコーポレイテッド | Systems and methods for high resolution mapping of tissues |
CN112168329A (en) | 2015-01-29 | 2021-01-05 | 波士顿科学医学有限公司 | Steam ablation system and method |
US9636164B2 (en) | 2015-03-25 | 2017-05-02 | Advanced Cardiac Therapeutics, Inc. | Contact sensing systems and methods |
BR112017024245A2 (en) | 2015-05-13 | 2018-07-17 | Nxthera, Inc. | "method for treating overactive bladder, and steam dispensing system". |
US10213253B2 (en) | 2015-12-24 | 2019-02-26 | Biosense Webster (Israel) Ltd. | Estimating a temperature during ablation |
US10575901B2 (en) | 2015-12-24 | 2020-03-03 | Biosense Webster (Israel) Ltd. | Estimating a temperature during ablation |
JP6923549B2 (en) | 2016-03-15 | 2021-08-18 | エピックス セラピューティクス,インコーポレイテッド | Improved system for irrigation cauterization |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
JP7129980B2 (en) | 2016-12-21 | 2022-09-02 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Steam cautery system and method |
AU2018205314B2 (en) | 2017-01-06 | 2023-06-15 | Boston Scientific Scimed, Inc. | Transperineal vapor ablation systems and methods |
EP3614946B1 (en) | 2017-04-27 | 2024-03-20 | EPiX Therapeutics, Inc. | Determining nature of contact between catheter tip and tissue |
KR101949940B1 (en) * | 2017-12-19 | 2019-02-19 | 주식회사 세비카 | Low temperature treatment apparatus capable of preventing damage to nerve tissue |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190053A (en) * | 1977-06-20 | 1980-02-26 | Rca Corporation | Apparatus and method for hyperthermia treatment |
US4375220A (en) * | 1980-05-09 | 1983-03-01 | Matvias Fredrick M | Microwave applicator with cooling mechanism for intracavitary treatment of cancer |
JPS5957650A (en) * | 1982-09-27 | 1984-04-03 | 呉羽化学工業株式会社 | Probe for heating body cavity |
CA1244889A (en) * | 1983-01-24 | 1988-11-15 | Kureha Chemical Ind Co Ltd | Device for hyperthermia |
US4601296A (en) * | 1983-10-07 | 1986-07-22 | Yeda Research And Development Co., Ltd. | Hyperthermia apparatus |
JPS6137259A (en) * | 1984-07-31 | 1986-02-22 | 菊地 真 | Heating apparatus for hyperthermia |
IL78756A0 (en) * | 1986-05-12 | 1986-08-31 | Biodan Medical Systems Ltd | Catheter and probe |
US5344435A (en) * | 1988-07-28 | 1994-09-06 | Bsd Medical Corporation | Urethral inserted applicator prostate hyperthermia |
US4967765A (en) * | 1988-07-28 | 1990-11-06 | Bsd Medical Corporation | Urethral inserted applicator for prostate hyperthermia |
FR2693116B1 (en) * | 1992-07-06 | 1995-04-28 | Technomed Int Sa | Urethral probe and apparatus for the therapeutic treatment of prostate tissue by thermotherapy. |
FR2639238B1 (en) * | 1988-11-21 | 1991-02-22 | Technomed Int Sa | APPARATUS FOR SURGICAL TREATMENT OF TISSUES BY HYPERTHERMIA, PREFERABLY THE PROSTATE, COMPRISING MEANS OF THERMAL PROTECTION COMPRISING PREFERABLY RADIOREFLECTIVE SCREEN MEANS |
US5007437A (en) * | 1989-06-16 | 1991-04-16 | Mmtc, Inc. | Catheters for treating prostate disease |
US5097829A (en) * | 1990-03-19 | 1992-03-24 | Tony Quisenberry | Temperature controlled cooling system |
FR2660561B1 (en) * | 1990-04-06 | 1994-05-13 | Technomed International | RECTAL PROBE. |
JPH05506174A (en) * | 1990-09-14 | 1993-09-16 | アメリカン・メディカル・システムズ・インコーポレーテッド | Combined hyperthermia and dilatation catheter |
JP3091253B2 (en) * | 1991-04-25 | 2000-09-25 | オリンパス光学工業株式会社 | Thermal treatment equipment |
US5304214A (en) * | 1992-01-21 | 1994-04-19 | Med Institute, Inc. | Transurethral ablation catheter |
US5413588A (en) * | 1992-03-06 | 1995-05-09 | Urologix, Inc. | Device and method for asymmetrical thermal therapy with helical dipole microwave antenna |
US5330518A (en) * | 1992-03-06 | 1994-07-19 | Urologix, Inc. | Method for treating interstitial tissue associated with microwave thermal therapy |
DE4207463C2 (en) * | 1992-03-10 | 1996-03-28 | Siemens Ag | Arrangement for the therapy of tissue with ultrasound |
GB9215042D0 (en) * | 1992-07-15 | 1992-08-26 | Microwave Engineering Designs | Microwave treatment apparatus |
US5391197A (en) * | 1992-11-13 | 1995-02-21 | Dornier Medical Systems, Inc. | Ultrasound thermotherapy probe |
EP0597463A3 (en) * | 1992-11-13 | 1996-11-06 | Dornier Med Systems Inc | Thermotherapiesonde. |
US5348554A (en) * | 1992-12-01 | 1994-09-20 | Cardiac Pathways Corporation | Catheter for RF ablation with cooled electrode |
US5405346A (en) * | 1993-05-14 | 1995-04-11 | Fidus Medical Technology Corporation | Tunable microwave ablation catheter |
WO1994028809A1 (en) * | 1993-06-10 | 1994-12-22 | Imran Mir A | Transurethral radio frequency ablation apparatus |
US5464437A (en) * | 1993-07-08 | 1995-11-07 | Urologix, Inc. | Benign prostatic hyperplasia treatment catheter with urethral cooling |
US5807395A (en) * | 1993-08-27 | 1998-09-15 | Medtronic, Inc. | Method and apparatus for RF ablation and hyperthermia |
AU4252596A (en) * | 1994-12-13 | 1996-07-03 | Torben Lorentzen | An electrosurgical instrument for tissue ablation, an apparatus, and a method for providing a lesion in damaged and diseased tissue from a mammal |
US5628770A (en) * | 1995-06-06 | 1997-05-13 | Urologix, Inc. | Devices for transurethral thermal therapy |
US5843144A (en) * | 1995-06-26 | 1998-12-01 | Urologix, Inc. | Method for treating benign prostatic hyperplasia with thermal therapy |
US6302878B1 (en) * | 1995-06-27 | 2001-10-16 | S.L.T. Japan Co., Ltd. | System for laser light irradiation to living body |
US5938692A (en) * | 1996-03-26 | 1999-08-17 | Urologix, Inc. | Voltage controlled variable tuning antenna |
US5676692A (en) * | 1996-03-28 | 1997-10-14 | Indianapolis Center For Advanced Research, Inc. | Focussed ultrasound tissue treatment method |
US5793070A (en) * | 1996-04-24 | 1998-08-11 | Massachusetts Institute Of Technology | Reduction of trapping effects in charge transfer devices |
US5733319A (en) * | 1996-04-25 | 1998-03-31 | Urologix, Inc. | Liquid coolant supply system |
US5987360A (en) * | 1996-05-03 | 1999-11-16 | Urologix, Inc. | Axial preferential thermal therapy |
US5800486A (en) * | 1996-06-17 | 1998-09-01 | Urologix, Inc. | Device for transurethral thermal therapy with cooling balloon |
US5861021A (en) * | 1996-06-17 | 1999-01-19 | Urologix Inc | Microwave thermal therapy of cardiac tissue |
US5792070A (en) * | 1996-08-30 | 1998-08-11 | Urologix, Inc. | Rectal thermosensing unit |
US6051018A (en) * | 1997-07-31 | 2000-04-18 | Sandia Corporation | Hyperthermia apparatus |
US5992419A (en) * | 1998-08-20 | 1999-11-30 | Mmtc, Inc. | Method employing a tissue-heating balloon catheter to produce a "biological stent" in an orifice or vessel of a patient's body |
US6122551A (en) * | 1998-12-11 | 2000-09-19 | Urologix, Inc. | Method of controlling thermal therapy |
-
1998
- 1998-12-11 US US09/210,033 patent/US6122551A/en not_active Expired - Lifetime
-
1999
- 1999-12-10 AU AU31188/00A patent/AU762862B2/en not_active Ceased
- 1999-12-10 JP JP2000586262A patent/JP2002531218A/en not_active Withdrawn
- 1999-12-10 WO PCT/US1999/029381 patent/WO2000033767A1/en active IP Right Grant
- 1999-12-10 EP EP99965224A patent/EP1148837B1/en not_active Expired - Lifetime
- 1999-12-10 CA CA002354587A patent/CA2354587A1/en not_active Abandoned
-
2000
- 2000-04-20 US US09/552,905 patent/US6490488B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2000033767A1 (en) | 2000-06-15 |
AU762862B2 (en) | 2003-07-10 |
US6490488B1 (en) | 2002-12-03 |
EP1148837A1 (en) | 2001-10-31 |
JP2002531218A (en) | 2002-09-24 |
AU3118800A (en) | 2000-06-26 |
EP1148837A4 (en) | 2009-03-11 |
US6122551A (en) | 2000-09-19 |
CA2354587A1 (en) | 2000-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1148837B1 (en) | System for controlling thermal therapy | |
US6009351A (en) | System and method for transurethral heating with rectal cooling | |
US6312391B1 (en) | Thermodynamic modeling of tissue treatment procedure | |
EP0632735B1 (en) | Dipole microwave antenna for asymmetrical thermal therapy | |
US5330518A (en) | Method for treating interstitial tissue associated with microwave thermal therapy | |
EP0634946B1 (en) | Gamma matched, helical dipole microwave antenna | |
US6216703B1 (en) | Therapeutic prostatic thermotherapy | |
AU708662B2 (en) | Method for treating benign prostatic hyperplasia with thermal therapy | |
AU678624B2 (en) | Gamma matched, helical dipole microwave antenna with tubular-shaped capacitor | |
US5464437A (en) | Benign prostatic hyperplasia treatment catheter with urethral cooling | |
US8301264B2 (en) | Thermal therapy temperature sensor calibration method | |
WO2000057811A1 (en) | Thermal therapy catheter | |
WO1997048450A1 (en) | Device for transurethral thermal therapy with cooling balloon | |
US20090157070A1 (en) | Medical treatment using pulsed energy | |
JP2020081880A (en) | Irrigation control during ablation | |
JPH0241979B2 (en) | ||
JP3841603B2 (en) | Heating treatment device | |
JPH06319816A (en) | Thermotherapic device | |
JPH07116274A (en) | Thermotherapic device | |
JPS625366A (en) | Warming apparatus for hyperthermia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010709 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090210 |
|
17Q | First examination report despatched |
Effective date: 20090624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 69944417 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61F0002000000 Ipc: A61B0018180000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 18/18 20060101AFI20120203BHEP |
|
RTI1 | Title (correction) |
Free format text: SYSTEM FOR CONTROLLING THERMAL THERAPY |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 576642 Country of ref document: AT Kind code of ref document: T Effective date: 20121015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 69944417 Country of ref document: DE Effective date: 20121122 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VOSSIUS AND PARTNER, CH |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR Ref country code: NL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120926 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 576642 Country of ref document: AT Kind code of ref document: T Effective date: 20120926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120926 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120926 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120926 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121231 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20121226 |
|
26N | No opposition filed |
Effective date: 20130627 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69944417 Country of ref document: DE Effective date: 20130702 Ref country code: DE Ref legal event code: R097 Ref document number: 69944417 Country of ref document: DE Effective date: 20130627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121210 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130702 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121226 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20131230 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20131220 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20131219 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121210 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20131220 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20150701 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20150701 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141210 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20161221 Year of fee payment: 18 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171211 |